K36 Therapeutics

🧬Creating breakthrough therapies for the unmet medical needs of cancer patients worldwide.
🔬Our clinical trial is now open!

[K36 Therapeutics @k36tx]

Do you know your patient's cytogenetics?

The K36-MMSET-001 trial is enrolling patients with relapsed/refractory multiple myeloma and t(4;14).

Learn more: https://t.co/UzgrnpkHvm

#MultipleMyeloma #ClinicalTrials #t414

[K36 Therapeutics @k36tx]

Do you know your myeloma cytogenetics?
Ask your care team:
• Have I had cytogenetic testing?
• Do I have t(4;14)?
• Are there clinical trials that may be right for me?
Knowledge opens doors. #MultipleMyeloma #ClinicalTrials #KnowYourCytogenetics #t414

[K36 Therapeutics @k36tx]

Happy Juneteenth from K36.
Today we celebrate freedom, resilience, and progress while honoring the diverse communities that strengthen our future.
#Juneteenth #FreedomDay

[K36 Therapeutics @k36tx]

Know your cytogenetics. If you have t(4;14) multiple myeloma, you may qualify for the MMSET clinical trial studying a novel approach targeting the MMSET/NSD2 pathway.
Talk with your doctor or visit https://t.co/eEk0FFJFhl

[K36 Therapeutics @k36tx]

How do you stop "shape-shifting" tumors?
K36 CEO Terry Connolly joins The Bio Report to discuss NSD2 biology, epigenetics, and our approach to developing first-in-class therapies for cancer.
Listen: https://t.co/mk6F0etIHr
#Biotech #Oncology #NSD2

[K36 Therapeutics @k36tx]

The K36 team is on site and looking forward to meeting investigators, partners, clinicians, and advocates.

Send us a message or email [email protected] to connect during #EHA26.

#MultipleMyeloma #CancerResearch #ClinicalTrials

[Joshua Richter, MD, FACP @JoshuaRichterMD]

@VincentRK kicking off this years IMWG summit. The room is electric with a sense of duty, science and cure. @IMFmyeloma bringing myeloma experts from across the globe together for the singular purpose of curing this disease. It’s an honor to be in this room #mmsm

[Mohamad Mohty @Mohty_EBMT]

Packed room. Endless enthusiasm. The IMWG Meeting in Stockholm is a powerful reminder that the myeloma community remains united by one mission: delivering better outcomes for all patients.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

And now, a live tribute to @H_Einsele from @VincentRK and the Plasma Cells - love it!!

@JoshuaRichterMD @szusmani @SurbhiSidanaMD @paurotero @mvmateos

[Daniel Auclair @AuclairDan]

Here we go @EHA_Hematology #EHA26 #EHA2026 Long line to get in. This will be an attendance record breaker!

[K36 Therapeutics @k36tx]

Great discussion from Terry Connolly and Shinta Cheng on NSD2, epigenetics, and the future of cancer treatment. Thanks Drug Discovery World for the feature. #Oncology https://t.co/MBwn8Ywzmz

[K36 Therapeutics @k36tx]

Great discussion from Terry Connolly and Dr. Shinta Cheng on NSD2 inhibition, KTX-1001, and the future of precision medicine in multiple myeloma. Worth a listen. #MultipleMyeloma #Oncology #Biotech

[K36 Therapeutics @k36tx]

Well deserved congratulations to @szusmani Dr Saad Usmani on receiving the Jean-Luc Harousseau Award at #COMy2026 for his contributions to advancing myeloma care and research.

[VJHemOnc @VJHemOnc]

At #iwMyeloma6 @DrSarahGooding discusses a novel, genetically driven vulnerability to mitosis targeting in multiple myeloma

#MultipleMyeloma #MMsm #Myeloma

[VJHemOnc @VJHemOnc]

We're starting off #iwMyeloma26 with Yubao Wang discussing the mechanistic basis of NSD2 as an oncogene

Stay tuned for more updates from the meeting!

#Myeloma #MMsm #MultipleMyeloma

[VJHemOnc @VJHemOnc]

#iwMyeloma26 | Mehmet Samur discusses genetics and epigenetics of early #myeloma

#MultipleMyeloma #MMsm

[Gareth Morgan @DrGarethMorgan1]

Study of NSD2 using a dTAG system reveals their molecular mechanism and oncogenic implications in t(4;14) multiple myeloma | Blood | American Society of Hematology Super glad this paper is out. An epic read from Dr Wang and colleagues https://t.co/ernu9rS43E

[K36 Therapeutics @k36tx]

@MTomasson @DrGarethMorgan1 We will be watching too!

[Gareth Morgan @DrGarethMorgan1]

The iwMM kicks off tomorrow morning one of the best and informative myeloma meetings each year-great program this year

[K36 Therapeutics @k36tx]

#NSD2 is having a moment at #iwMyeloma 2026.
High-risk MM. Epigenetic dependency. Real targets.
We’re paying attention.
#NSD2 #Myeloma